fosaprepitant
Sign in to saveAlso known as Ivemend®, MK-0517, L-758,298, L-758298, Fosaprepitantum
Fosaprepitant, sold under the brand names Emend (US) and Ivemend (EU) among others, is an antiemetic medication, administered intravenously. It is a prodrug of aprepitant.
Research
269 papers- Fosaprepitant for postoperative nausea and vomiting in patients undergoing laparoscopic gastrointestinal surgery: a randomised trial.British journal of anaesthesia · 2023
- Aprepitant, fosaprepitant and risk of ifosfamide-induced neurotoxicity: a systematic review.Cancer chemotherapy and pharmacology · 2022
- The clinical research study for fosaprepitant to prevent chemotherapy-induced nausea and vomiting: A review.Advances in clinical and experimental medicine : official organ Wroclaw Medical University · 2023
- Fosaprepitant Dimeglumine: A Review in the Prevention of Nausea and Vomiting Associated with Chemotherapy.Drugs · 2016
- Aprepitant and fosaprepitant drug interactions: a systematic review.British journal of clinical pharmacology · 2017
via PubMed
~3 min read
Encyclopedic overview
1 sectionsContents
- References
{{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 416448532 | image = Fosaprepitant.svg | image_class = skin-invert-image | alt = Skeletal formula of fosaprepitant | width = 255 | image2 = Fosaprepitant-3D-spacefill.png | image_class2 = bg-transparent | alt2 = Space-filling model of the fosaprepitant molecule
| tradename = Emend, Ivemend | Drugs.com = | MedlinePlus = a604003 | licence_EU = yes | DailyMedID = Fosaprepitant | licence_US = Fosaprepitant | pregnancy_AU = B2 | pregnancy_AU_comment = | pregnancy_category = | routes_of_administration = Intravenous | ATC_prefix = A04 | ATC_suffix = AD12
Excerpted from Wikipedia’s “fosaprepitant” article, available under the CC BY-SA 4.0 licence.
Available in 8 languages
via Wikidata sitelinks · CC0